In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Zynerba Pharmaceuticals, Inc.. Trade Record

NASDAQ:ZYNE Zynerba Pharmaceuticals, Inc. stock gains 15.16% Exit Sep 6, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart ZYNE Aug 27, 2018, priceSeries
About Zynerba Pharmaceuticals, Inc.

Zynerba Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its products candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. The company was founded in 2007 and is headquartered in Devon, Pennsylvania.

Trade Information
Trade Type
LONG
ReliabilityScore™
99.60
Entry Date
Aug 27, 2018
Entry Price
6.47
Sell Date
Sep 6, 2018
Sell Price
7.45
Net Gain
15.16%
Hold Time
7 Trading Days